File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor

TitleHistological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor
Authors
Issue Date2010
PublisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.org
Citation
Annals Of Surgical Oncology, 2010, v. 17 n. 8, p. 2184-2192 How to Cite?
AbstractBackground: Whether the TNM staging system is applicable after neoadjuvant chemoradiation in esophageal cancer is controversial. The aim of this study was to evaluate the prognostic value of histopathological regression of the primary tumor in postchemoradiated patients. Materials and Methods: The pretherapeutic and pathological ypTNM stages of patients who have had neoadjuvant chemoradiation followed by esophagectomy were analyzed. The percentage of residual viable cells of the primary tumor (ypV) and other clinicopathological factors were tested for their prognostic value. Results: Of 175 recruited patients, 55 (31.4%) achieved pathological complete response. The median survival of these 55 patients was significantly longer than those with other disease stages (124.8 vs 21.1 months) (P <.001). Gender, ypT, ypN, ypTNM, and ypV stage were significant prognostic factors in univariate analysis. In patients without nodal metastases, the median survival in patients with residual viable cells in the primary tumor (ypV?) was 24.6 months, compared with that of 124.8 months in those with no viable cells (ypV0) (P =.043). In those who had nodal metastases, the median survival of patients with ypV0 and ypV? were 21.2 months and 17.4 months respectively (P =.37). Cox regression analysis showed that male gender, high percentage of residual viable cells (ypV), and positive nodal status (ypN1) were independent predictors of poor prognosis. Conclusions: In patients who underwent neoadjuvant chemoradiation therapy, histopathological regression of the primary tumor indicated by percentage of residual viable cells is an important prognostic factor in addition to nodal status and gender. © The Author(s) 2010.
Persistent Identifierhttp://hdl.handle.net/10722/65490
ISSN
2015 Impact Factor: 3.655
2015 SCImago Journal Rankings: 1.902
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTong, DKHen_HK
dc.contributor.authorLaw, Sen_HK
dc.contributor.authorKwong, DLWen_HK
dc.contributor.authorChan, KWen_HK
dc.contributor.authorLam, AKYen_HK
dc.contributor.authorWong, KHen_HK
dc.date.accessioned2010-08-19T08:24:22Z-
dc.date.available2010-08-19T08:24:22Z-
dc.date.issued2010en_HK
dc.identifier.citationAnnals Of Surgical Oncology, 2010, v. 17 n. 8, p. 2184-2192en_HK
dc.identifier.issn1068-9265en_HK
dc.identifier.urihttp://hdl.handle.net/10722/65490-
dc.description.abstractBackground: Whether the TNM staging system is applicable after neoadjuvant chemoradiation in esophageal cancer is controversial. The aim of this study was to evaluate the prognostic value of histopathological regression of the primary tumor in postchemoradiated patients. Materials and Methods: The pretherapeutic and pathological ypTNM stages of patients who have had neoadjuvant chemoradiation followed by esophagectomy were analyzed. The percentage of residual viable cells of the primary tumor (ypV) and other clinicopathological factors were tested for their prognostic value. Results: Of 175 recruited patients, 55 (31.4%) achieved pathological complete response. The median survival of these 55 patients was significantly longer than those with other disease stages (124.8 vs 21.1 months) (P <.001). Gender, ypT, ypN, ypTNM, and ypV stage were significant prognostic factors in univariate analysis. In patients without nodal metastases, the median survival in patients with residual viable cells in the primary tumor (ypV?) was 24.6 months, compared with that of 124.8 months in those with no viable cells (ypV0) (P =.043). In those who had nodal metastases, the median survival of patients with ypV0 and ypV? were 21.2 months and 17.4 months respectively (P =.37). Cox regression analysis showed that male gender, high percentage of residual viable cells (ypV), and positive nodal status (ypN1) were independent predictors of poor prognosis. Conclusions: In patients who underwent neoadjuvant chemoradiation therapy, histopathological regression of the primary tumor indicated by percentage of residual viable cells is an important prognostic factor in addition to nodal status and gender. © The Author(s) 2010.en_HK
dc.languageeng-
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.orgen_HK
dc.relation.ispartofAnnals of Surgical Oncologyen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsThe Author(s)-
dc.subject.meshCarcinoma, Squamous Cell - mortality - pathology - therapy-
dc.subject.meshCell Survival-
dc.subject.meshChemotherapy, Adjuvant-
dc.subject.meshEsophageal Neoplasms - mortality - pathology - therapy-
dc.subject.meshEsophagectomy-
dc.titleHistological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factoren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1068-9265&volume=17&issue=8&spage=2184&epage=2192&date=2010&atitle=Histological+regression+of+squamous+esophageal+carcinoma+assessed+by+percentage+of+residual+viable+cells+after+neoadjuvant+chemoradiation+is+an+important+prognostic+factor-
dc.identifier.emailLaw, S: slaw@hku.hken_HK
dc.identifier.emailKwong, DLW: dlwkwong@hku.hken_HK
dc.identifier.emailChan, KW: hrmtckw@hku.hken_HK
dc.identifier.authorityLaw, S=rp00437en_HK
dc.identifier.authorityKwong, DLW=rp00414en_HK
dc.identifier.authorityChan, KW=rp00330en_HK
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1245/s10434-010-0995-2en_HK
dc.identifier.pmid20217248en_HK
dc.identifier.pmcidPMC2899023-
dc.identifier.scopuseid_2-s2.0-77955012425en_HK
dc.identifier.hkuros174358-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77955012425&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume17en_HK
dc.identifier.issue8en_HK
dc.identifier.spage2184en_HK
dc.identifier.epage2192en_HK
dc.identifier.eissn1534-4681en_HK
dc.identifier.isiWOS:000279653600030-
dc.publisher.placeUnited Statesen_HK
dc.description.otherSpringer Open Choice, 01 Dec 2010-
dc.identifier.scopusauthoridTong, DKH=8670837000en_HK
dc.identifier.scopusauthoridLaw, S=7202241293en_HK
dc.identifier.scopusauthoridKwong, DLW=15744231600en_HK
dc.identifier.scopusauthoridChan, KW=16444133100en_HK
dc.identifier.scopusauthoridLam, AKY=7403657165en_HK
dc.identifier.scopusauthoridWong, KH=36485841700en_HK
dc.identifier.citeulike6871813-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats